Oral administration of arsenic trioxide in the treatment of acute promyelocytic leukaemia and accelerated phase chronic myeloid leukaemia: an Australian single-centre study

Oral idarubicin in the treatment of acut

Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia

✍ S. T. A. Malik; J. Tucker; A. Z. S. Rohatiner; W. Brace; T. A. Lister 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 307 KB

Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/ day). No complete remissions or return to chronic phase CML were observed. A fall in the per